A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.
Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.
Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.
Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.
Levels of serum calprotectin are significantly associated with the risk of disease relapse among tumour necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis, researchers report.
Findings from a randomized trial indicate that treatment with the interleukin-1α and -1β inhibitor lutikizumab does not improve pain or imaging outcomes among patients with erosive hand osteoarthritis.
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213336
Patients with large vessel involvement when diagnosed with biopsy-confirmed giant cell arteritis have a substantially increased risk of death relative to patients with no large vessel involvement, Italian researchers report.
Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.